glp-1 agonist and gastroparesis receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Your guide to GLP-1 side

ICD-10 codes to identify the outcome are included in supplementary table S1

Multiple studies highlight its potential applications in prevention

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA

The advent of incretin mimetics such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has enriched the armamentarium for diabetes management owing to their glycaemic as well as extra-glycaemic benefits

Glycemic monitoring with CGMs, glucose-lowering agents (GLP-1 receptor agonists), innovative insulin delivery systems, and mental health check-ins are just a few updates to the ADA 2025 Standards of Care.

WEDNESDAY, June 10, 2026 (HealthDay News) -- Continuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) into early pregnancy seems not to be associat